

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	hours per response:
	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Shanmugam Muthusamy</u> (Last) (First) (Middle) C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST (Street) BAUDETTE MN 56623 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ANI PHARMACEUTICALS INC [ANIP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>HEAD OF R&D, COO-NOVITIUM OPS</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/19/2024</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								47,407	D	
Common Stock	01/19/2024		s ⁽¹⁾		4,524	D	\$55.57 ⁽²⁾	903,312	I	Held by Esjay LLC ⁽³⁾
Common Stock	01/22/2024		s ⁽¹⁾		5,692	D	\$55.95 ⁽⁴⁾	897,620	I	Held by Esjay LLC ⁽³⁾
Common Stock	01/23/2024		s ⁽¹⁾		15,000	D	\$56.44 ⁽⁵⁾	882,620	I	Held by Esjay LLC ⁽³⁾
Common Stock								5,000	I	Held by SS Pharma LLC ⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$55.03 to \$56.00, inclusive.
- The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$55.63 to \$56.21, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$56.00 to \$57.11, inclusive.
- The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Remarks:

/s/ Muthusamy Shanmugam,
by attorney-in-fact Meredith 01/23/2024
W. Cook

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

